Pharmacokinetics and Half-Life of Protein Therapeutics

about

Clinical pharmacology of bispecific antibody constructs.Half-life extended biotherapeutics.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds

P2860

Q38364459-3ABDF17E-48F4-4B51-8936-C0923031A14D Q38770067-95F42706-3BB5-4308-A539-7634238A50D7 Q58869554-3BC90F44-BEEC-4B4C-BBF4-EDD52B4FD5C4

P2860

Pharmacokinetics and Half-Life of Protein Therapeutics

Item

http://www.wikidata.org/entity/Q58869604

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2012

@uk

name

Pharmacokinetics and Half-Life of Protein Therapeutics

@en

Pharmacokinetics and Half-Life of Protein Therapeutics

@nl

type

Item

label

Pharmacokinetics and Half-Life of Protein Therapeutics

@en

Pharmacokinetics and Half-Life of Protein Therapeutics

@nl

prefLabel

Pharmacokinetics and Half-Life of Protein Therapeutics

@en

Pharmacokinetics and Half-Life of Protein Therapeutics

@nl

P1476

Pharmacokinetics and Half-Life of Protein Therapeutics

@en

P2093

Bernd Meibohm

http://www.w3.org/2001/XMLSchema#string

P2860

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

Pharmacokinetic/pharmacodynamic studies in drug product development.

Protein drug oral delivery: the recent progress.

ADMET in silico modelling: towards prediction paradise?

Emerging trends in oral delivery of peptide and protein drugs.

Pharmacokinetic aspects of biotechnology products.

Target-mediated drug disposition and dynamics.

Paving the critical path: how can clinical pharmacology help achieve the vision?

FcRn: the neonatal Fc receptor comes of age.

Population pharmacokinetics of therapeutic monoclonal antibodies.

P304

23-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/9783527644827.CH2

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime